By IDSE News Staff
The FDA issued an emergency use authorization (EUA) for tocilizumab (Actemra, Genentech) for the treatment of hospitalized adults and pediatric patients (24 months of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Tocilizumab is not authorized for use in outpatients with COVID-19.